Clinical trial · Interventional

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors

NCT00002947CI-TRIAL-00014983terminatedPhase 1ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of indium In 111 pentetreotide in treating patients who have refractory cancer.

Conditions

Conditions (12)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Brain and Central Nervous System Tumors	—	UNRESOLVED	—
Childhood Langerhans Cell Histiocytosis	Childhood Langerhans Cell Histiocytosis	ONTOLOGY_EXACT	0.98
Gastrointestinal Carcinoid Tumor	Digestive System Neuroendocrine Tumor G1	ALIAS	0.90
Head and Neck Cancer	Malignant Head and Neck Neoplasm	ALIAS	0.90
Intraocular Melanoma	Uveal Melanoma	ALIAS	0.90
Islet Cell Tumor	Pancreatic Neuroendocrine Tumor	ALIAS	0.90
Kidney Cancer	Malignant Kidney Neoplasm	CURATED_EXACT	0.92
Lung Cancer	Malignant Lung Neoplasm	CURATED_EXACT	0.92
Melanoma (Skin)	Melanoma	ONTOLOGY_EXACT

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
indium In 111 pentetreotide	Radiation	—	UNRESOLVED

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

DISEASE CHARACTERISTICS: Histologically proven malignancy with no alternate treatments available Measurable or evaluable progressive disease Somatostatin receptors present on tumor and uptake demonstrated on diagnostic scan with OctreoScan

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 3 months Hematopoietic: Platelet count at least 100,000/mm3 Absolute neutrophil count at least 1,500/mm3 Hepatic: Total bilirubin no greater than 2.0 mg/dL Renal: Creatinine clearance at least 40 mL/min Other: No active infections Not HIV positive No coexisting medical condition Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior wide field radiation therapy Surgery: Recovery from prior surgery

References

Publications (0)

Data not yet available

No reference posted for this study.

Registry

Dates and enrollment

Start: Oct 1, 1996
Primary completion: Aug 1, 2004
Completion: Aug 1, 2004
First posted: Mar 26, 2004
Last update posted: Jul 2, 2014
Enrollment: 35 (estimated)
Lead sponsor: Yale University OTHER
Collaborators: National Cancer Institute (NCI)
Keywords: stage IV renal cell cancer, recurrent renal cell cancer, extensive stage small cell lung cancer, recurrent small cell lung cancer, metastatic gastrointestinal carcinoid tumor, recurrent gastrointestinal carcinoid tumor, gastrinoma, insulinoma, recurrent islet cell carcinoma, thyroid gland medullary carcinoma, prolactin-producing pituitary tumor, iris melanoma, ciliary body and choroid melanoma, medium/large size, extraocular extension melanoma, recurrent intraocular melanoma, stage IV melanoma, recurrent melanoma, WDHA syndrome, somatostatinoma, pancreatic polypeptide tumor, glucagonoma, childhood Langerhans cell histiocytosis, metastatic pheochromocytoma, recurrent pheochromocytoma, pulmonary carcinoid tumor, stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity, recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity, stage III neuroendocrine carcinoma of the skin, recurrent neuroendocrine carcinoma of the skin

Data updated 22 days agoSource updated Jul 2, 2014source: clinicaltrials

Brief summary (as posted)

Conditions (12)

Interventions (1)

Eligibility (as posted)

Publications (0)

Locations by country (1)